AVIR - Atea Pharmaceuticals Inc Short Interest
This article provides a detailed financial snapshot of Atea Pharmaceuticals Inc (AVIR), focusing on its short interest, key financial metrics, stock performance, and insider/institutional ownership. It includes information such as market capitalization, income, sales, price-to-book ratio, EPS, short float percentage, volatility, and various performance indicators over different periods.
AVIR - Atea Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Atea Pharmaceuticals Inc (AVIR), including its stock performance, volatility, key financial ratios, and insider/institutional ownership. It highlights various metrics such as market capitalization, P/E ratio, sales, EPS growth rates, and analyst recommendations, offering a comprehensive snapshot for potential investors.
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article provides financial information for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content offers a brief financial overview within the TradingView platform.
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article focuses on the "Price to book forward" metric for Atea Pharmaceuticals, Inc., traded on NASDAQ under the symbol AVIR. It appears to be a financial data page from TradingView, providing an overview of the company's financial information within that platform. The content primarily lists navigation and platform features rather than in-depth financial analysis.
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR
This article provides the enterprise value to EBITDA forward for Atea Pharmaceuticals, Inc. (AVIR) as part of the Blue Ocean Alternative Trade System (BOATS) on TradingView. It appears to be a financial data point without further analysis or context on its significance.
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
This article provides a financial snapshot for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a larger financial platform, indicating a value change and percentage change for a specific period. The content primarily shows the company's ticker, market, and a brief status, with no further analytical details.
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR
This article displays the "Price to earnings forward" information for Atea Pharmaceuticals, Inc. (BOATS:AVIR) on the TradingView platform. It shows the company's ticker symbol, market status, and available financial data sections. The content prominently features the company name and stock symbol, indicating it's a financial data point entry rather than an analytical piece.
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR)
This article provides an overview of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) stock performance, financial estimates, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, historical highs and lows, earnings details, and future revenue expectations. The article also includes frequently asked questions about investing in AVIR and information on the company's next earnings report.
AVIR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Atea Pharmaceuticals, Inc. (AVIR) stock, including current price, historical performance, analyst price targets, and future earnings estimates. Analysts predict AVIR's price could range from $6.00 to $10.00, with earnings expected on August 6, 2026. The stock currently trades at $4.35 and does not pay dividends.
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD clinical trial, evaluating bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C virus (HCV) treatment outside North America. The trial enrolled over 880 treatment-naïve patients across 17 countries, with topline results expected around year-end 2026. This, alongside the C-BEYOND trial in North America, represents the first global Phase 3 head-to-head trials of direct-acting antivirals for HCV, aiming to provide a best-in-class regimen for the widespread global challenge of HCV.
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant
Atea Pharmaceuticals director Polly A. Murphy reported equity compensation, including the exercise of 29,600 Restricted Stock Units (RSUs) into common stock, bringing her total direct holdings to 121,745 shares. She also received a new grant of 37,700 stock options with an exercise price of $4.36, vesting monthly over a year, and 26,700 new RSUs set to vest by June 18, 2027. These transactions highlight ongoing equity-based compensation for the director.
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants
Atea Pharmaceuticals director Jerome M. Adams exercised 29,600 restricted stock units (RSUs) into common stock and received new grants of 37,700 stock options and 26,700 RSUs. These transactions are described as routine equity compensation, converting previously awarded equity into share ownership and providing new incentives without open-market buying or selling. After these activities, Adams directly holds 92,350 common shares.
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs
Atea Pharmaceuticals director Bruno Lucidi engaged in equity compensation activities, exercising 29,600 restricted stock units into Common Stock, leading to a direct holding of 142,350 Common shares. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, both subject to time-based vesting. These transactions were reported in a Form 4 filing and highlight changes in Lucidi's equity ownership rather than open-market trading.
AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Atea Pharmaceuticals (AVIR) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights a recent Form 3 filing on June 24, 2025, and summarizes the results of the company's June 20, 2025 Annual Meeting of Stockholders where directors were re-elected, and auditor ratification and say-on-pay proposals were approved. The platform also offers AI-generated insights, impact scoring, and sentiment analysis for each filing.
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Atea Pharmaceuticals Inc. for June 23, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article notes Atea Pharmaceuticals' stock symbol as AVIR and its recent performance.
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity
Franklin M. Berger, a director at Atea Pharmaceuticals, Inc. (AVIR), increased his equity exposure through several transactions on June 18, 2026. These included the conversion of 29,600 restricted stock units into common shares, receipt of a stock option for 37,700 shares, and a grant of 26,700 new restricted stock units. Following these transactions, Berger directly holds 536,097 common shares of the company.
Atea Pharmaceuticals elects directors and approves proposals at annual meeting
Atea Pharmaceuticals (NASDAQ:AVIR) held its 2026 Annual Meeting of Stockholders, electing three Class III directors and approving all proposals, including the ratification of KPMG LLP as the independent public accounting firm and an advisory vote on executive compensation. The company's stock has gained 38% over the past six months, and InvestingPro analysis suggests it is undervalued with price targets between $6 and $10. Recent news also detailed Atea's Q1 2026 earnings, showing a slight miss on EPS but highlighting a strong cash position and promising Phase 1 results for its Hepatitis C treatment.
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Atea Pharmaceuticals Inc for June 23. Form 4s detail changes in beneficial ownership of company stock by insiders. The article itself is very brief, mainly serving as an announcement of the filing rather than providing detailed analysis of its contents.
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR)
Atea Pharmaceuticals director Howard Berman was granted new equity awards, including stock options for 37,700 shares at an exercise price of $4.36 and 26,700 restricted stock units. These awards, detailed in a Form 4 SEC filing, are part of his compensation and are subject to vesting conditions based on his continued service through June 2027. This transaction reflects an increase in his potential ownership in the company without any open-market purchases.
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director
Atea Pharmaceuticals director Arthur S. Kirsch has been granted 37,700 stock options with an exercise price of $4.36 per share, vesting monthly between June 2026 and June 2027. He also received 26,700 restricted stock units (RSUs), which will vest in a single installment by June 2027 or at the next annual stockholder meeting, contingent on his continued service. This equity award is part of insider trading activity reported via a Form 4 SEC filing.
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards
Atea Pharmaceuticals director Bruce Polsky exercised 29,600 restricted stock units and received new equity awards on June 18, 2026. These new awards include a stock option for 37,700 shares at $4.36 per share and 26,700 restricted stock units, both vesting over time, subject to continued service. The transactions reported through a Form 4 filing indicate compensation-related activity with no open-market share sales.
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com
This article reports that Atea Pharmaceuticals Inc filed a Form 8K on June 22. The brief announcement provides no further details but is accompanied by general market data and related news from Investing.com. It highlights the company's filing of a standard regulatory document.
Atea Pharmaceuticals elects directors and approves proposals at annual meeting
Atea Pharmaceuticals (NASDAQ:AVIR) held its 2026 Annual Meeting of Stockholders, electing three Class III directors and approving all presented proposals. Stockholders ratified KPMG LLP as the independent public accounting firm and approved the compensation of named executive officers. The company's stock has gained 38% in the past six months, and InvestingPro analysis suggests it is undervalued with price targets between $6 and $10.
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com
This article reports on a Form 8K filing by Atea Pharmaceuticals Inc, specifically for June 22. The brief provides the essential details of the filing as published by Investing.com. It is a very short news item confirming the existence of the regulatory filing.
Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes
Atea Pharmaceuticals announced the results of its 2026 annual stockholder meeting, where 74.65% of shares outstanding were represented. Stockholders elected three Class III directors, ratified KPMG LLP as the independent registered public accounting firm, and approved the executive compensation program on an advisory basis. These outcomes indicate strong shareholder participation and support for the company's governance and compensation practices.
Atea Pharmaceuticals Inc (AVIR) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Atea Pharmaceuticals Inc (AVIR)'s financial health, noting its weak status and low operating efficiency with a financial score of 6.09. It details various financial dimensions such as Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, but indicates that relevant data for these metrics have not yet been disclosed by the company. The report ranks Atea Pharmaceuticals 291 out of 389 in the Biotechnology & Medical Research industry.
Atea Pharmaceuticals (AVIR) AGM 2026 Summary
This article summarizes Atea Pharmaceuticals' (AVIR) 2026 Annual General Meeting. Key points included the re-election of three Class III directors, ratification of KPMG as the auditor, and advisory approval of executive compensation. The company also provided updates on its advanced Phase 3 HCV and HEV programs, and its financial position with significant cash reserves.
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Atea Pharmaceuticals Inc (AVIR), detailing its business segments and regional revenue contributions. However, the company has not yet disclosed relevant data for FY2020, FY2021, and FY2022. The available information indicates that the United States currently contributes 0.00% to the company's revenue, with no specific business segment data provided.
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Atea Pharmaceuticals Inc (AVIR) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current market data shows AVIR trading at $4.270, with a market cap of $333.60 million.
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Atea Pharmaceuticals Inc (AVIR), noting its current valuation score of 6.81, which ranks it 291 out of 388 in its industry. The company's P/E ratio is reported as -2.01, significantly below its recent high but above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Atea Pharmaceuticals Inc (AVIR), focusing on its stock price momentum, support and resistance levels, and key indicators. The analysis shows AVIR's current price momentum score is 7.00, suggesting a range-bound swing trading opportunity between resistance at $4.68 and support at $4.05. The technical indicators and moving averages collectively suggest a "Sell" signal for the stock based on current data.
Atea Pharmaceuticals Inc (AVIR) Institutional Confidence
Atea Pharmaceuticals Inc (AVIR) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. The current institutional shareholding proportion is 70.93%, which is a 6.88% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.46% of outstanding shares.
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year?
This article from MSN asks whether medical stocks are lagging Atea Pharmaceuticals (AVIR) this year. Without further content, it's impossible to determine the answer or supporting details. The title suggests a comparison of AVIR's performance against the broader medical sector.
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
This article reports a significant increase in the price target for Atea Pharmaceuticals (AVIR) shares. The new price target has been raised by 33.33% to $8.16. This adjustment likely reflects a more positive outlook from analysts regarding the company's future stock performance.
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
Atea Pharmaceuticals (AVIR) recently saw its price target increased by 33.33% to $8.16. This adjustment reflects new analyst sentiment regarding the company's future stock performance. Investors and market watchers may find this updated target significant for their investment decisions.
Atea Pharmaceuticals - I'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR)
Atea Pharmaceuticals (AVIR) has received a buy rating ahead of key Phase 3 hepatitis C data expected in mid-2026. The company's BEM/RZR treatment aims for a high sustained virologic response and low drug-drug interactions, targeting a differentiated, short-duration, pan-genotypic HCV regimen. While AVIR has a cash runway through 2027, its future success and potential acquisition interest are contingent on positive Phase 3 results, especially given competition from Gilead and AbbVie.
AVIR News | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR)
This article provides recent news and analysis for ATEA PHARMACEUTICALS INC (NASDAQ:AVIR), including its current stock price and key financial updates. It highlights recent press releases regarding Q1 financial results, pipeline advancements in HCV and HEV treatments, and presentations at the EASL Congress 2026. The news also covers analyst takes on the stock's performance.
Atea Pharmaceuticals (Nasdaq:AVIR) - Stock Analysis
This Simply Wall St analysis provides a comprehensive overview of Atea Pharmaceuticals (AVIR), detailing its valuation, growth prospects, financial health, past performance, and recent news. The report highlights AVIR as a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics, particularly for Hepatitis C and E, while noting its current unprofitability and declining earnings. It also includes analyst price targets, competitive landscape, and a timeline of key company announcements and clinical trial updates.
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Atea Pharmaceuticals announced Phase 1 results at the EASL Congress 2026, demonstrating that its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C virus (HCV) has a low risk of drug-drug interaction, supporting co-administration with common medications. Additionally, the company presented preclinical data for AT-587, a potential first-in-class direct-acting antiviral for Hepatitis E virus (HEV), highlighting its high in vitro antiviral potency and in vivo efficacy. These findings suggest that both BEM/RZR and AT-587 could address significant unmet medical needs in HCV and HEV treatment, respectively.
No hepatitis E drugs: Atea antiviral 30–150x more potent in lab
Atea Pharmaceuticals presented Phase 1 data at the EASL Congress 2026 demonstrating that its fixed-dose hepatitis C regimen bemnifosbuvir/ruzasvir (BEM/RZR) has a low risk of drug-drug interactions with common medications. Additionally, preclinical data for AT-587, a potential first-in-class hepatitis E antiviral, showed high in vitro potency and in vivo efficacy, being 30-150 times more potent than existing off-label treatments. These findings support simplifying HCV treatment for patients on multiple medications and addressing a critical unmet need for HEV therapy.
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Atea Pharmaceuticals announced positive Phase 1 results for its fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C, demonstrating a low risk of drug-drug interactions with common medications. The company also presented promising preclinical data for AT-587, a potential first-in-class treatment for Hepatitis E, which is expected to advance to human studies mid-year. These findings were presented at the EASL Congress 2026.
Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks
This article highlights three prominent penny stocks: Atea Pharmaceuticals (AVIR), Duluth Holdings (DLTH), and Stitch Fix (SFIX). It provides an overview of each company's financial health, market capitalization, operations, and recent performance, emphasizing their potential for growth despite current pre-revenue or unprofitable statuses. The article notes the overall market rise and the projected annual earnings growth.
AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Atea Pharmaceuticals' (AVIR) official regulatory documents, including 10-K, 10-Q, 8-K forms, and insider trading filings. It details recent filings such as a Form 4 disclosing a stock option grant to director Howard Berman and an 8-K summarizing the 2025 Annual Meeting results where directors were re-elected and auditor ratification and say-on-pay proposals were approved. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock
Polly A. Murphy, a director at Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), purchased 6,100 shares of the company’s common stock for $25,446 on May 18, 2026. This transaction increased her direct holdings to 92,145 shares. The purchase comes as the company continues to focus on its strong cash reserves and strategic plans for its Hepatitis C and E programs despite a recent slight miss on Q1 2026 EPS.
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock
Atea Pharmaceuticals director Polly A. Murphy purchased 6,100 shares of Common Stock on the open market at a weighted average price of $4.1715 per share on May 18, 2026. This transaction increased her direct ownership to 92,145 shares. The filing, an amended Form 4/A, corrected the transaction date from May 18, 2025, to May 18, 2026.
Atea (AVIR) director adds 6,100 shares in open-market purchase
Atea Pharmaceuticals Director Polly A. Murphy purchased 6,100 shares of common stock on May 18, 2025, through an open-market transaction. The shares were acquired at a weighted average price of $4.1715 per share, ranging from $4.14 to $4.19. Following this acquisition, Murphy directly holds 92,145 shares of the company's common stock, reflecting a neutral filing impact and positive sentiment.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss
Atea Pharmaceuticals reported Q1 2026 earnings, missing EPS forecasts by $0.01 with an EPS of -$0.57. This unexpected miss caused the stock to plunge 15.53% in after-hours trading. Despite the setback, the company highlighted a strong cash position of $256 million, providing a runway through 2027, and remains committed to advancing its Hepatitis C and E programs with key milestones expected.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss
Atea Pharmaceuticals reported a Q1 2026 EPS of -$0.57, missing the forecast of -$0.56, which led to a 15.53% drop in stock price during after-hours trading. Despite the miss, the company maintains a strong cash position of $256 million, expected to last through 2027, and is focusing on its Hepatitis C Phase III program and a new Hepatitis E program. Key milestones for HCV and HEV programs are anticipated within existing cash resources, with a generally positive outlook from Wall Street analysts.
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The presentations will include new clinical study results supporting their fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV), and preclinical data for AT-587, their lead clinical candidate for hepatitis E virus (HEV). These presentations underscore Atea’s ongoing progress in its antiviral pipeline and its commitment to advancing new treatment options for patients with viral hepatitis.
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Atea Pharmaceuticals reported a strong financial position with $256 million in cash and equivalents, projecting a cash runway through 2027. The company is progressing with its global Phase 3 HCV program, anticipating top-line data releases mid-year and year-end, and has expanded its pipeline to include a new HEV program, planning to initiate a first-in-human study mid-year. Management also highlighted a potential best-in-class profile for its HCV regimen, aiming for a strong position in the $2.6 billion global HCV market.
